Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    October 2021
  1. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  2. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available


  3. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    PubMed     Abstract available


  4. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  5. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    


  6. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  7. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available


  8. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available


  9. PLYM A, Penney KL, Kalia S, Kraft P, et al
    Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer.
    J Natl Cancer Inst. 2021 Apr 1. pii: 6207974. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  10. KIBEL AS, Inman BA, Pachynski RK, Vu T, et al
    Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
    J Natl Cancer Inst. 2021 Feb 25. pii: 6149481. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  11. KENSLER KH, Pernar CH, Mahal BA, Nguyen PL, et al
    Racial/ethnic variation in PSA testing and prostate cancer incidence following the 2012 U.S.P.S.T.F. recommendation.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955778. doi: 10.1093.
    PubMed     Abstract available


  12. ETZIONI R, Nyame YA
    Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955775. doi: 10.1093.
    PubMed    


  13. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    


    October 2020
  14. HURWITZ LM, Agalliu I, Albanes D, Barry KH, et al
    Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.
    J Natl Cancer Inst. 2020 Oct 3. pii: 5917632. doi: 10.1093.
    PubMed     Abstract available


  15. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    


    September 2020
  16. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    


    August 2020
  17. DRAGO JZ, Gonen M, Thanarajasingam G, Sacks CA, et al
    Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.
    J Natl Cancer Inst. 2020 Aug 28. pii: 5898636. doi: 10.1093.
    PubMed     Abstract available


  18. DARST BF, Dadaev T, Saunders E, Sheng X, et al
    Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898200. doi: 10.1093.
    PubMed     Abstract available


  19. ROBERTS AW, Eiffert S, Wulff-Burchfield EM, Dusetzina SB, et al
    Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer.
    J Natl Cancer Inst. 2020 Aug 17. pii: 5893484. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  20. LEHRER S, Rheinstein PH
    Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    J Natl Cancer Inst. 2020 Jun 30. pii: 5865274. doi: 10.1093.
    PubMed    


  21. MADAN RA, Antonarakis ES, Drake CG, Fong L, et al
    Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    J Natl Cancer Inst. 2020;112:562-573.
    PubMed     Abstract available


    May 2020
  22. JEMAL A, Culp MB, Ma J, Islami F, et al
    Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    J Natl Cancer Inst. 2020 May 20. pii: 5837113. doi: 10.1093.
    PubMed     Abstract available


    April 2020

  23. Erratum to "Lifetime benefits and harms of PSA-based risk screening for prostate cancer".
    J Natl Cancer Inst. 2020 Apr 23. pii: 5824307. doi: 10.1093.
    PubMed    


  24. GULATI R, Morgan TM, A'mar T, Psutka SP, et al
    Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
    J Natl Cancer Inst. 2020;112:384-390.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: